[ad_1]
However, study results show that the vaccine is less effective in protecting against coronavirus, a strain first reported in the Republic of South Africa (PAR), when mild to moderate illnesses are included.
The final results of the study were released Thursday following the release of the vaccine’s primary efficacy indicators in late January.
The third phase of the UK study involved 15,000 18-84 old people. 27 percent of the study participants were over 65 years old. people. The protection of the vaccine against mild, moderate and severe cases of COVID-19 infection with a previous strain of coronavirus was found to be equivalent to 96.4%.
“Novavax” last
© Vida Press
For the coronavirus B.1.1.7, which is more contagious, the efficacy of the vaccine was 89.7.
PAR in a much smaller phase 2b study of 2,600 people found the vaccine to be 48.6%. effective, although among HIV-uninfected volunteers, the rate was higher, at 55.4%.
No part of this publication may be reproduced without the written permission of ELTA.
[ad_2]
